Trending Biotech Stocks in the News – DNDN, GILD, ARNA, CLSN
Houston, TX – February 7, 2013 — (Net PR News) – AnotherWinningTrade.com delivers quality trading ideas for the elite investor that has the financial wherewithal and market nimbleness to profit on small moves in a stock’s price. Become a member and you will be provided with real-time alerts intended to provide you with the opportunity to make profitable trades. To receive our FREE, comprehensive newsletter, visit AnotherWinningTrade.com.
Stocks that are being watched this morning are: NASDAQ:DNDN, NASDAQ:GILD, NASDAQ:ARNA, NASDAQ:CLSN
Dendreon Corporation (NASDAQ:DNDN) reported that, to review its financial results for the fourth quarter and full year 2012, on Monday, February 25, 2013, at 9:00 a.m. ET / 6:00 a.m. PT, the company’s management will host a conference call.
Dendreon Corporation started the session with the price of $6.17, traded in the day range of $6.10 – $6.66 and closed the session at $6.65. The stock was a positive mover in the prior session and moved ahead +7.95%. A look at prior trends of DNDN, the stock was a gainer in its 5 days performance and escalated +11.76%, while the monthly trend of the stock was hot as it scored a strong bullish movement of +10.65%.
How Should Investors React To DNDN Now? Find Out In This TREND ANALYSIS REPORT
Gilead Sciences, Inc. (NASDAQ:GILD) exchanged 11.65 million shares and its average trading capacity remained 8.85 million shares. GILD fell -1.55% and finished the day at $39.91. GILD traded in the day range of $39.55 – $40.62, while its 52 week range was $21.91 – $41.34. GILD moved up +5.41% in its one month’s trend and its 3 month’s trend was also up as it surged +18.29%. EPS of the stock was $1.63.
Get A Free Report And Detailed Analysis On GILD CLICK HERE To Read
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) revealed that, in New York City at The Waldorf Astoria, the company has planned to present a corporate overview at two upcoming investor conferences.
On February 12, 2013, at 1:30 p.m. Eastern Time (10:30 a.m. Pacific Time), at the 15th Annual BIO CEO & Investor Conference and the other one is Leerink Swann Global Healthcare Conference, which is being held on February 13, 2013, at 2:30 p.m. Eastern Time (11:30 a.m. Pacific Time).
How Should Investors Trade ARNA Now? Don’t Trade ARNA Until You Read This TREND ANALYSIS REPORT
Arena Pharmaceuticals, Inc. closed at $8.72 by scoring +1.04%, while the market capitalization of ARNA was $1.89 billion. ARNA traded with volume of 5.65 million shares, as compared to the average trading volume of 11.12 million shares. The 5 days graph showed the upbeat performance of +0.11%. The shares outstanding of the stock remained 217.29 million and its beta factor remained 0.16.
Celsion Corporation (NASDAQ:CLSN) was among the top volume gainers and traded with volume of 6.71 million shares in the last session, as compared to average volume of 4.91 million shares. During the previous trading session, the stock showed a bearish movement of -2.44% to the closing price of $1.20. CLSN remained within the day’s range of $1.18 – $1.30, while the 52 week range was $1.13 – $9.44. The 5 days performance graph showed it as a percentage loser -84.46%.
Is CLSN A Solid Investment At These Levels? Find Out Exactly Where CLSN Is Headed With This TREND ANALYSIS REPORT
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.